retatrutide and type 1 diabetes Retatrutide, a GIP, GLP-1 glucagon receptor agonist, for people with 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Medscape | The investigational triple

By targeting all three at once, Retatrutide 50mg produces a broader range of metabolic effects including appetite suppression, improved insulin sensitivity, and direct liver fat reduction that single or dual receptor agonists cannot fully replicate

While these typically do not require immediate intervention, they should be monitored, and patients should be counseled about symptoms that would necessitate treatment

If youre facing one, youre probably thinking: What do I do now

This might relate to GIPs potential effects on food reward pathways or metabolic signaling

And if I think like, oh, this is like cardiovascular disease, then then we need to be focusing there, not waiting until things change

Dietary recommendations for the management of gastrointestinal symptoms in patients treated with GLP-1 receptor agonist